Advertisement
APVO vs NIKI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APVO is a Hold and NIKI is a Hold.
APVO sees MACD Histogram crosses below signal line
APVO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 41 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APVO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in 141 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.498). P/E Ratio (0.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NIKI's RSI Oscillator dives into oversold zone
The RSI Oscillator for NIKI moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NIKI just turned positive on October 27, 2026. Looking at past instances where NIKI's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +15.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIKI advanced for three days, in 157 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NIKI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIKI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIKI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.056) is normal, around the industry mean (3.498). P/E Ratio (-0.832) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. NIKI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIKI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
APVO | NIKI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 92 | |
PRICE GROWTH RATING 1..100 | 95 | 97 | |
P/E GROWTH RATING 1..100 | 97 | 6 | |
SEASONALITY SCORE 1..100 | n/a | 38 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NIKI's Valuation (39) in the Pharmaceuticals Major industry is in the same range as APVO (52) in the Biotechnology industry. This means that NIKI’s stock grew similarly to APVO’s over the last 12 months.
NIKI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as APVO (100) in the Biotechnology industry. This means that NIKI’s stock grew similarly to APVO’s over the last 12 months.
NIKI's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as APVO (100) in the Biotechnology industry. This means that NIKI’s stock grew similarly to APVO’s over the last 12 months.
APVO's Price Growth Rating (95) in the Biotechnology industry is in the same range as NIKI (97) in the Pharmaceuticals Major industry. This means that APVO’s stock grew similarly to NIKI’s over the last 12 months.
NIKI's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for APVO (97) in the Biotechnology industry. This means that NIKI’s stock grew significantly faster than APVO’s over the last 12 months.
| APVO | NIKI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Stochastic ODDS (%) | N/A | N/A |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 76% | 3 days ago 81% |
| Declines ODDS (%) | 2 days ago 90% | 7 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APVO’s FA Score shows that 0 FA rating(s) are green while NIKI’s FA Score has 1 green FA rating(s).
- APVO’s FA Score: 0 green, 5 red.
- NIKI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APVO’s TA Score shows that 3 TA indicator(s) are bullish while NIKI’s TA Score has 4 bullish TA indicator(s).
- APVO’s TA Score: 3 bullish, 3 bearish.
- NIKI’s TA Score: 4 bullish, 2 bearish.
Price Growth
APVO (@Biotechnology) experienced а -20.59% price change this week, while NIKI (@Biotechnology) price change was -9.04% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
APVO is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
APVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, APVO has been closely correlated with GNPX. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if APVO jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To APVO | 1D Price Change % | ||
|---|---|---|---|---|
| APVO | 100% | -4.42% | ||
| GNPX - APVO | 92% Closely correlated | +1.46% | ||
| ICU - APVO | 92% Closely correlated | -3.06% | ||
| MLEC - APVO | 78% Closely correlated | N/A | ||
| NCEL - APVO | 50% Loosely correlated | +4.00% | ||
| NIKI - APVO | 46% Loosely correlated | -8.00% | ||
More | ||||
NIKI and
Correlation & Price change
A.I.dvisor indicates that over the last year, NIKI has been loosely correlated with HLSQ. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NIKI jumps, then HLSQ could also see price increases.
| Ticker / NAME | Correlation To NIKI | 1D Price Change % | ||
|---|---|---|---|---|
| NIKI | 100% | -8.00% | ||
| HLSQ - NIKI | 60% Loosely correlated | -37.43% | ||
| CANF - NIKI | 48% Loosely correlated | -1.19% | ||
| APVO - NIKI | 46% Loosely correlated | -4.42% | ||
| ICU - NIKI | 45% Loosely correlated | -3.06% | ||
| MLEC - NIKI | 45% Loosely correlated | N/A | ||
More | ||||